Angiogenesis and apoptosis.
暂无分享,去创建一个
[1] M. Buyse,et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Rakesh K. Jain,et al. Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.
[3] S. Cory,et al. The Bcl-2 protein family: arbiters of cell survival. , 1998, Science.
[4] J. Folkman,et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[5] W. Reeves,et al. Seroprevalence of human papillomavirus type 16 infection in the United States. , 2002, The Journal of infectious diseases.
[6] R. Kerbel,et al. What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? , 2002, Cancer research.
[7] G. Semenza,et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. , 2000, Genes & development.
[8] S. Fox,et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.
[9] Lars Holmgren,et al. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression , 1995, Nature Medicine.
[10] Y. Ogiso,et al. A comprehensive system to explore p53 mutations. , 1998, American journal of clinical pathology.
[11] B Vojnovic,et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. , 2001, Cancer research.
[12] E. Weiss,et al. Targetting of the N‐terminal domain of the human papillomavirus type 16 E6 oncoprotein with monomeric scFvs blocks the E6‐mediated degradation of cellular p53 , 1999, Journal of molecular recognition : JMR.
[13] N. Goldstein,et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. , 1997, The American journal of pathology.
[14] C. Eaves,et al. Unfulfilled promise of endostatin in a gene therapy-xenotransplant model of human acute lymphocytic leukemia. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[15] R K Jain,et al. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. , 1990, Journal of the National Cancer Institute.
[16] M. Gondo,et al. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene , 1999, Nature Biotechnology.
[17] D. Hanahan,et al. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.
[18] P. Hahnfeldt,et al. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. , 2002, Journal of the National Cancer Institute.
[19] C. Dinney,et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[20] C. Coleman,et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy , 1994 .
[21] G. Pruneri,et al. Kinetics and viability of circulating endothelial cells as surrogate angiogenesis marker in an animal model of human lymphoma. , 2001, Cancer research.
[22] K. Dameron,et al. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. , 1994, Science.
[23] R. Timpl,et al. Local endostatin treatment of gliomas administered by microencapsulated producer cells , 2001, Nature Biotechnology.
[24] M. Knopp,et al. Special techniques for imaging blood flow to tumors. , 2002, Cancer journal.
[25] A. Feldman,et al. Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. , 2001, Journal of the National Cancer Institute.
[26] D. Haller,et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. , 1996, Journal of the National Cancer Institute.
[27] M. Chamberlain. Recurrent supratentorial malignant gliomas in children. Long-term salvage therapy with oral etoposide. , 1997, Archives of neurology.
[28] S. Stacker,et al. VEGF-D is an X-linked/AP-1 Regulated Putative Onco-angiogen in Human Glioblastoma Multiforme , 2001, Molecular medicine.
[29] L. Ellis,et al. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] Arnold J. Levine,et al. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53 , 1990, Cell.
[31] R. D'Amato,et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. , 2001, Cancer research.
[32] N. Muzyczka,et al. Adeno-associated virus–mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo , 2002, Cancer Gene Therapy.
[33] R. Nicosia,et al. Angiogenesis-dependent tumor spread in reinforced fibrin clot culture. , 1983, Cancer research.
[34] G. Yancopoulos,et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.
[35] Figg,et al. 8:45-9:00. Using PET 18F-FDG, 11CO, and 15O-water for Monitoring Prostate Cancer During a Phase II Anti-angiogenic Drug Trial with Thalidomide. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.
[36] D. Lowy,et al. Identification of the HPV‐16 E6 protein from transformed mouse cells and human cervical carcinoma cell lines. , 1987, The EMBO journal.
[37] P. Okunieff,et al. Intratumoral administration of endostatin plasmid inhibits vascular growth and perfusion in MCa-4 murine mammary carcinomas. , 2001, Cancer research.
[38] A. Rosato,et al. Differential effects of angiostatin, endostatin and interferon-α1 gene transfer on in vivo growth of human breast cancer cells , 2002, Gene Therapy.
[39] Lars Holmgren,et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[40] D. DiMaio,et al. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[41] Yihai Cao,et al. Continuous intravascular secretion of endostatin in mice from transduced hematopoietic stem cells. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[42] M. Plummer,et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis , 2003, British Journal of Cancer.
[43] D. Hicklin,et al. Effect of p53 Status on Tumor Response to Antiangiogenic Therapy , 2002, Science.
[44] D. Hicklin,et al. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. , 2001, Cancer research.
[45] A. Hengstermann,et al. siRNA targeting of the viral E6 oncogene efficiently kills human papillomavirus-positive cancer cells , 2003, Oncogene.
[46] W. Quint,et al. Technical Advance Novel Short-Fragment PCR Assay for Highly Sensitive Broad-Spectrum Detection of Anogenital Human Papillomaviruses , 1998 .
[47] R. Xavier,et al. Tumor Induction of VEGF Promoter Activity in Stromal Cells , 1998, Cell.
[48] M. Scheffner,et al. Induction of apoptosis in human papillomaviruspositive cancer cells by peptide aptamers targeting the viral E6 oncoprotein. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[49] J. Roth,et al. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. , 1996, Gynecologic oncology.
[50] Harald zur Hausen,et al. Papillomaviruses Causing Cancer: Evasion From Host-Cell Control in Early Events in Carcinogenesis , 2000 .
[51] L. Chin,et al. Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.
[52] J. Folkman,et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.
[53] T. Friedmann. THE DEVELOPMENT OF HUMAN GENE THERAPY , 1999 .
[54] G. Viale,et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[55] R. D'Amato,et al. Comparative evaluation of the antitumor activity of antiangiogenic proteins delivered by gene transfer , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[56] Gabriele Bergers,et al. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.
[57] D. Hanahan,et al. Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma , 1991, Cell.
[58] G. Nolan,et al. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[59] R. D'Amato,et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. , 2001, Journal of the National Cancer Institute.
[60] F. Holding,et al. Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts. , 1999, The Journal of infectious diseases.
[61] H. Bernard,et al. The human papillomavirus type 11 and 16 E6 proteins modulate the cell-cycle regulator and transcription cofactor TRIP-Br1. , 2003, Virology.
[62] R. Kerbel,et al. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. , 2000, The journal of investigative dermatology. Symposium proceedings.
[63] A. Feldman,et al. Adenovirus-mediated endostatin delivery results in inhibition of mammary gland tumor growth in C3(1)/SV40 T-antigen transgenic mice. , 2002, Cancer research.
[64] J. Folkman,et al. Heterogeneity of angiogenic activity in a human liposarcoma: a proposed mechanism for "no take" of human tumors in mice. , 2001, Journal of the National Cancer Institute.
[65] Anthony Atala,et al. Continuous release of endostatin from microencapsulated engineered cells for tumor therapy , 2001, Nature Biotechnology.
[66] R. Barakat,et al. Salvage weekly paclitaxel in recurrent ovarian cancer. , 1997, Seminars in oncology.
[67] David J. Yang,et al. Assessment of antiangiogenic effect using 99mTc-EC-endostatin. , 2002, Cancer biotherapy & radiopharmaceuticals.
[68] S. Radulović,et al. Daily oral etoposide in metastatic breast cancer. , 1996, Anti-cancer drugs.
[69] E. Villiers. Human Pathogenic Papillomavirus Types: An Update , 1994 .
[70] D. Hanahan,et al. Upregulation of fibroblast growth factors and their receptors during multi-stage epidermal carcinogenesis in K14-HPV16 transgenic mice. , 1996, Oncogene.
[71] E. Chang,et al. Downmodulation of bFGF-binding protein expression following restoration of p53 function , 2001, Cancer Gene Therapy.
[72] L. Ellis,et al. Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. , 2000, Cancer research.
[73] A. Giaccia,et al. Antiangiogenic therapy and p53. , 2002, Science.
[74] A. Schulze,et al. Sequential activation of cyclin E and cyclin A gene expression by human papillomavirus type 16 E7 through sequences necessary for transformation , 1995, Journal of virology.
[75] T. Hausamen,et al. Schedule- and dose-intensified paclitaxel as weekly 1-hour infusion in pretreated solid tumors: results of a phase I/II trial. , 1996, Seminars in oncology.
[76] B. Lowell,et al. Adipose tissue mass can be regulated through the vasculature , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[77] R. Kauppinen,et al. The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice , 2002, Cancer Gene Therapy.
[78] R. Kerbel,et al. Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. , 1995, Anti-cancer drugs.
[79] J. Folkman. Tumor angiogenesis: therapeutic implications. , 1971, The New England journal of medicine.
[80] J. Folkman,et al. Generation of multiple angiogenesis inhibitors by human pancreatic cancer. , 2001, Cancer research.
[81] R. D'Amato,et al. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[82] P. Carmeliet,et al. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.
[83] S. Agelaki,et al. Treatment of non-small-cell lung cancer with prolonged oral etoposide. , 1998, American journal of clinical oncology.
[84] M. Detmar,et al. Thrombospondin-2: a potent endogenous inhibitor of tumor growth and angiogenesis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[85] S. Rafii,et al. Impaired recruitment of bone-marrow–derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth , 2001, Nature Medicine.
[86] P. Hahnfeldt,et al. Antiangiogenic Therapy and p53 , 2002, Science.
[87] J. Folkman,et al. TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION , 1972, The Journal of experimental medicine.
[88] Peter Bohlen,et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity , 2000 .
[89] J. Folkman,et al. Clinical translation of angiogenesis inhibitors , 2002, Nature Reviews Cancer.
[90] H. Gabra,et al. Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer. , 1996, British Journal of Cancer.
[91] 19 The Logic of Anti-angiogenic Gene Therapy , 1999 .
[92] G. Nicolson,et al. Separable growth and migration factors for large-cell lymphoma cells secreted by microvascular endothelial cells derived from target organs for metastasis. , 1992, British Journal of Cancer.
[93] D. Hanahan,et al. Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.